1Day Africa director Zacharia Kafuko argues it is imperative that Moderna and Pfizer share samples to other researchers to support next-generation COVID vaccine development.

The authors of our advanced market commitment (AMC) report detail in The Hill how a relatively small commitment in the form of an AMC could spur the development of a vaccine worth $1.08 trillion.

Read coverage our our UK Pandemic Ethics Accelerator launch event in London. 1Day Sooner partnered with the UK Pandemic Ethics Accelerator and sponsored The Ethics of Controlled Human Infection Model Studies for Mitigating Pandemic Risks, a report that offers a blueprint to shortening the time frame to develop vaccines during emerging pandemics without cutting corners.

1Day Africa director Zacharia Kafuko and 1Day Sooner founder Josh Morrison consulted in article by Vox about the need for tuberculosis challenge trials in endemic settings like Malawi.

Celebrated vaccinologist Stanley Plotkin and 1Day Sooner founder Josh Morrison explain why human challenge trials for coronaviruses will be important for next-generation vaccine development.

Dr. Andrea Cox of Johns Hopkins University makes the case for human challenge trials for hepatitis C based on her experience running a non-challenge trial in the field.

The UK has approved the world’s first COVID-19 human challenge trials. Read an interview with Jacob, 1Day Sooner UK volunteer, in GAVI’s #VaccinesWork series.

Listen to four 1Day Sooner volunteers talk about why they want to be deliberately exposed to SARS-CoV-2 to accelerate research at an Imagine! Belfast event here.

Read about our advocacy to publish the protocol for the UK COVID-19 challenge trial in the British Medical Journal and The Guardian.

1Day Sooner and the University College London Bioethics Society recently hosted a panel about the current role of COVID-19 human challenge trials featuring experts Meta Roestenberg, Seema Shah, and Matt Memoli. Watch it here.